P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB

• R. Nakamura,
• R. Hendricks,
• R. Dokhaei,
• M. Susilo,
• D. Wilson,
• S. Trudel,
• A. Cohen,
• S. J. Harrison,
• A. Krishnan,
• R. Fonseca,
• J. I. Adamkewicz,
• M. Li,
• C. Wong,
• J. Cooper,
• T. Sumiyoshi

Affiliations

R. Nakamura

1 Genentech, Inc., South San Francisco, CA, United States of America

R. Hendricks

1 Genentech, Inc., South San Francisco, CA, United States of America

R. Dokhaei

1 Genentech, Inc., South San Francisco, CA, United States of America

M. Susilo

1 Genentech, Inc., South San Francisco, CA, United States of America

D. Wilson

1 Genentech, Inc., South San Francisco, CA, United States of America

S. Trudel

2 Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada

A. Cohen

3 Abramson Cancer Center and University of Pennsylvania, Philadelphia, PA, United States of America

S. J. Harrison

4 Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Melbourne, VIC, Australia

A. Krishnan

5 City of Hope, Duarte, CA

R. Fonseca

6 Mayo Clinic in Arizona, Phoenix, AZ, United States of America

J. I. Adamkewicz

1 Genentech, Inc., South San Francisco, CA, United States of America

M. Li

1 Genentech, Inc., South San Francisco, CA, United States of America

C. Wong

1 Genentech, Inc., South San Francisco, CA, United States of America

J. Cooper

1 Genentech, Inc., South San Francisco, CA, United States of America

T. Sumiyoshi

1 Genentech, Inc., South San Francisco, CA, United States of America